Sustained release Aricept and eribulin key near-term R&D projects for Eisai
This article was originally published in Scrip
Executive Summary
Eisai expects a new high-dose, sustained release formulation to help sustain sales of its top product, the Alzheimer's disease therapy Aricept (donepezil), while the microtubule dynamics inhibitor eribulin will lead the Japanese firm's near-term push into the oncology sector.